WO2001076621A3 - Methods and compositions for treating neoplasms - Google Patents

Methods and compositions for treating neoplasms Download PDF

Info

Publication number
WO2001076621A3
WO2001076621A3 PCT/US2001/011089 US0111089W WO0176621A3 WO 2001076621 A3 WO2001076621 A3 WO 2001076621A3 US 0111089 W US0111089 W US 0111089W WO 0176621 A3 WO0176621 A3 WO 0176621A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
compositions
methods
treating neoplasms
neuraminidase
Prior art date
Application number
PCT/US2001/011089
Other languages
French (fr)
Other versions
WO2001076621A2 (en
Inventor
Ellis L Kline
Original Assignee
Ellis L Kline
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellis L Kline filed Critical Ellis L Kline
Priority to DK01924706T priority Critical patent/DK1272211T3/en
Priority to EP01924706A priority patent/EP1272211B1/en
Priority to CA002406128A priority patent/CA2406128A1/en
Priority to IL15213001A priority patent/IL152130A0/en
Priority to AU5133601A priority patent/AU5133601A/en
Priority to DE60128793T priority patent/DE60128793T2/en
Priority to AU2001251336A priority patent/AU2001251336B2/en
Publication of WO2001076621A2 publication Critical patent/WO2001076621A2/en
Publication of WO2001076621A3 publication Critical patent/WO2001076621A3/en
Priority to IL152130A priority patent/IL152130A/en
Priority to AU2006252030A priority patent/AU2006252030B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention comprises the periodic administration of a solution of neuraminidase to a patient with a neoplasm until the neoplasm has receded. The administration of the solution of neuraminidase can be administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration. The present invention is effective in treating a wide variety of neoplasms.
PCT/US2001/011089 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms WO2001076621A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK01924706T DK1272211T3 (en) 2000-04-07 2001-04-05 Methods and compositions for the treatment of neoplasms
EP01924706A EP1272211B1 (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms
CA002406128A CA2406128A1 (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms
IL15213001A IL152130A0 (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms
AU5133601A AU5133601A (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms
DE60128793T DE60128793T2 (en) 2000-04-07 2001-04-05 Method and composition for the treatment of neoplasms
AU2001251336A AU2001251336B2 (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms
IL152130A IL152130A (en) 2000-04-07 2002-10-06 Compositions for treating neoplasms
AU2006252030A AU2006252030B2 (en) 2000-04-07 2006-12-13 Methods and compositions for treating neoplasms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19553800P 2000-04-07 2000-04-07
US60/195,538 2000-04-07

Publications (2)

Publication Number Publication Date
WO2001076621A2 WO2001076621A2 (en) 2001-10-18
WO2001076621A3 true WO2001076621A3 (en) 2002-05-23

Family

ID=22721792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011089 WO2001076621A2 (en) 2000-04-07 2001-04-05 Methods and compositions for treating neoplasms

Country Status (12)

Country Link
US (2) US6977169B2 (en)
EP (1) EP1272211B1 (en)
AT (1) ATE363915T1 (en)
AU (3) AU2001251336B2 (en)
CA (1) CA2406128A1 (en)
CY (1) CY1107489T1 (en)
DE (1) DE60128793T2 (en)
DK (1) DK1272211T3 (en)
ES (1) ES2287116T3 (en)
IL (2) IL152130A0 (en)
PT (1) PT1272211E (en)
WO (1) WO2001076621A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
MX2012009755A (en) 2010-02-26 2012-09-12 Novo Nordisk As Stable antibody containing compositions.
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6673696B2 (en) 2012-09-28 2020-03-25 クライン，エリス Glycosidase regimen for the treatment of infectious diseases
CA2896899A1 (en) * 2013-01-18 2014-07-24 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
MX2020007024A (en) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Recombinant human sialidases, sialidase fusion proteins, and methods of using the same.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259550A (en) * 1962-12-21 1966-07-05 Nat Res Dev Production of neuraminidase
US4071408A (en) * 1976-11-01 1978-01-31 Research Corporation Neuraminidase
WO1994007516A1 (en) * 1992-10-02 1994-04-14 Alberta Research Council Anti-inflammatory, tolerogenic and immunostimulatory properties of carbohydrate binding-proteins
US5736133A (en) * 1991-04-09 1998-04-07 Molecular Rx, Inc. Method and composition for the treatment of a individual infected with an immunodeficiency virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377074A (en) * 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
US4071407A (en) * 1976-11-16 1978-01-31 The Board Of Trustees Of The University Of Alabama Novel maltase enzyme produced by a new yeast strain
RU2137131C1 (en) * 1992-12-18 1999-09-10 Молекьюлар Ар-Экс, Инк. Hybrid cellular line (variants), antibody preparation (variants), method of diagnosis of cerebrospinal sclerosis in human (variants), method of treatment of human, polypeptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259550A (en) * 1962-12-21 1966-07-05 Nat Res Dev Production of neuraminidase
US4071408A (en) * 1976-11-01 1978-01-31 Research Corporation Neuraminidase
US5736133A (en) * 1991-04-09 1998-04-07 Molecular Rx, Inc. Method and composition for the treatment of a individual infected with an immunodeficiency virus
WO1994007516A1 (en) * 1992-10-02 1994-04-14 Alberta Research Council Anti-inflammatory, tolerogenic and immunostimulatory properties of carbohydrate binding-proteins

Also Published As

Publication number Publication date
WO2001076621A2 (en) 2001-10-18
AU5133601A (en) 2001-10-23
US20010036455A1 (en) 2001-11-01
DE60128793T2 (en) 2008-02-07
DK1272211T3 (en) 2007-10-01
US7842314B2 (en) 2010-11-30
AU2001251336B2 (en) 2006-09-14
DE60128793D1 (en) 2007-07-19
US20060034821A1 (en) 2006-02-16
PT1272211E (en) 2007-09-14
EP1272211B1 (en) 2007-06-06
US6977169B2 (en) 2005-12-20
EP1272211A2 (en) 2003-01-08
AU2006252030B2 (en) 2009-01-15
ES2287116T3 (en) 2007-12-16
AU2006252030A1 (en) 2007-01-11
CA2406128A1 (en) 2001-10-18
IL152130A (en) 2009-11-18
ATE363915T1 (en) 2007-06-15
CY1107489T1 (en) 2013-03-13
IL152130A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
CY1107489T1 (en) METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT
EA200200778A1 (en) METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
WO2003015843A3 (en) Administration of insulin by jet injection
IS6702A (en) Fentanyl nasal drug formulation
NO333189B1 (en) Use of buprenorphine for the preparation of a transdermal dosage form for the treatment of drug dependence, and seen extensively in such dosage forms.
MY139203A (en) Pharmaceutical composition
HRP20161197T1 (en) 24-norudca for treating autoimmune hepatitis
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
ME00523B (en) Pharmaceutical solutions of levosimendan
MXPA03011480A (en) Aqueous cilostazol preparation for injection.
RU2005130023A (en) APPLICATION OF ERYTHROPOETHIN IN RESTORATION AFTER A STROKE
EP0647616A4 (en) Zinc tranexamate compound.
ES2167189A1 (en) Pharmaceutical formulation for intravenous or intramuscular octreotide administration
RU2008138124A (en) METHOD FOR PREVENTION AND TREATMENT OF DISEASES CAUSED BY HUMAN SUBSTYPE H5N1 VIRUS INFLUENZA VIRUS USING INTERFERON INDUCTOR AND NEURAMINIDASE INHIBITOR
PT900082E (en) USE OF PYRIDYLPYPERAZINE AND PYRIMIDYLPIPERAZINE FOR THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF TOXICOMANIA DISTURBACTIONS
WO2000067699A3 (en) Pharmaceutical compositions for treating malaria
WO2003092767A3 (en) A method for inhibiting platelet aggregation
UA39708A (en) Method for treating postamputation pain syndrome
EP1011672A4 (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
CA2368184A1 (en) Method and means for treating post-polio syndrome
WO2001049299A3 (en) Prevention of ironotecan induced diarrhea with activated carbon
HUP0301026A2 (en) Use of arginine the preparation of a medicament for the prevention and treatment the side effects associated with the intravenous administration of pharmaceuticals
DE69918124T2 (en) Compositions and devices for transdermal administration of fenoldopam
RU2001106194A (en) A method for the treatment of aspirin bronchial asthma
UA41200A (en) Method for conservative treatment of osteoarthrosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 152130

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2406128

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001251336

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001924706

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001924706

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001924706

Country of ref document: EP